JP7726487B2 - 呼吸器合胞体ウイルス阻害剤の合成及び使用 - Google Patents

呼吸器合胞体ウイルス阻害剤の合成及び使用

Info

Publication number
JP7726487B2
JP7726487B2 JP2022544247A JP2022544247A JP7726487B2 JP 7726487 B2 JP7726487 B2 JP 7726487B2 JP 2022544247 A JP2022544247 A JP 2022544247A JP 2022544247 A JP2022544247 A JP 2022544247A JP 7726487 B2 JP7726487 B2 JP 7726487B2
Authority
JP
Japan
Prior art keywords
group
compound
amino
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511152A5 (https=
JP2023511152A (ja
Inventor
パン，チェン
リュ，シァシー
チェン，メンフェイ
イン，ウェイ
ゴン，チャオジュン
ハン，ジェン
シェン，ウェイ
リ，ダンビン
ゾウ，ガン
ユアン，ハイチン
ジム ウー，ジェン
Original Assignee
スージョウ アーク バイオファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スージョウ アーク バイオファーマシューティカル カンパニー リミテッド filed Critical スージョウ アーク バイオファーマシューティカル カンパニー リミテッド
Publication of JP2023511152A publication Critical patent/JP2023511152A/ja
Publication of JP2023511152A5 publication Critical patent/JP2023511152A5/ja
Application granted granted Critical
Publication of JP7726487B2 publication Critical patent/JP7726487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022544247A 2020-01-22 2021-01-21 呼吸器合胞体ウイルス阻害剤の合成及び使用 Active JP7726487B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010075139.8 2020-01-22
CN202010075139.8A CN113149977A (zh) 2020-01-22 2020-01-22 一类呼吸道合胞病毒抑制剂的合成与用途
PCT/CN2021/073042 WO2021147947A1 (zh) 2020-01-22 2021-01-21 一类呼吸道合胞病毒抑制剂的合成与用途

Publications (3)

Publication Number Publication Date
JP2023511152A JP2023511152A (ja) 2023-03-16
JP2023511152A5 JP2023511152A5 (https=) 2024-01-30
JP7726487B2 true JP7726487B2 (ja) 2025-08-20

Family

ID=76881779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544247A Active JP7726487B2 (ja) 2020-01-22 2021-01-21 呼吸器合胞体ウイルス阻害剤の合成及び使用

Country Status (6)

Country Link
US (1) US12582661B2 (https=)
EP (1) EP4095136A4 (https=)
JP (1) JP7726487B2 (https=)
KR (1) KR20220130761A (https=)
CN (2) CN113149977A (https=)
WO (1) WO2021147947A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149977A (zh) * 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
CN116425754A (zh) * 2021-12-30 2023-07-14 苏州爱科百发生物医药技术有限公司 芳杂双环化合物及其抗病毒用途
CN120794971A (zh) * 2024-04-10 2025-10-17 广州医科大学 二氨基嘧啶化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521709A (ja) 2011-08-11 2014-08-28 エフ．ホフマン−ラ ロシュ アーゲー 呼吸器合胞体ウイルス疾患の治療及び予防のための化合物
JP2016520637A (ja) 2013-06-04 2016-07-14 アクチュラム・ライフ・サイエンス・アクチエボラーグ ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP2017503843A (ja) 2014-01-24 2017-02-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎ−［（３−アミノオキセタン−３−イル）メチル］−２−（１，１−ジオキソ−３，５−ジヒドロ−１，４−ベンゾチアゼピン−４−イル）−６−メチル−キナゾリン−４−アミンの製造のための方法
JP2018520188A (ja) 2015-07-16 2018-07-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形
JP2018524386A (ja) 2015-07-22 2018-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760230A (en) * 1996-10-11 1998-06-02 Bayer Aktiengesellschaft 4, 4'-bridged bis-2, 4-diaminoquinazolines
CN113149977A (zh) 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521709A (ja) 2011-08-11 2014-08-28 エフ．ホフマン−ラ ロシュ アーゲー 呼吸器合胞体ウイルス疾患の治療及び予防のための化合物
JP2016520637A (ja) 2013-06-04 2016-07-14 アクチュラム・ライフ・サイエンス・アクチエボラーグ ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP2017503843A (ja) 2014-01-24 2017-02-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎ−［（３−アミノオキセタン−３−イル）メチル］−２−（１，１−ジオキソ−３，５−ジヒドロ−１，４−ベンゾチアゼピン−４−イル）−６−メチル−キナゾリン−４−アミンの製造のための方法
JP2018520188A (ja) 2015-07-16 2018-07-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形
JP2018524386A (ja) 2015-07-22 2018-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2019年，Vol. 62, No. 13，p. 6003-6014

Also Published As

Publication number Publication date
WO2021147947A1 (zh) 2021-07-29
EP4095136A4 (en) 2023-07-05
EP4095136A1 (en) 2022-11-30
CN115023423B (zh) 2025-07-25
CN115023423A (zh) 2022-09-06
JP2023511152A (ja) 2023-03-16
KR20220130761A (ko) 2022-09-27
US20230090060A1 (en) 2023-03-23
US12582661B2 (en) 2026-03-24
CN113149977A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
JP7795521B2 (ja) 抗ウイルス剤としての官能化ペプチド
TW202302571A (zh) 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物
US11866433B2 (en) Diarylthiohydantoin compound as androgen receptor antagonist
JP7726487B2 (ja) 呼吸器合胞体ウイルス阻害剤の合成及び使用
JP7624093B2 (ja) ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
AU2020255702B2 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN114380837A (zh) 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
CN114075227B (zh) 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
JP2025003592A (ja) 抗ウイルス１，３－ジ－オキソ－インデン化合物
US20250011292A1 (en) Novel rhodanine derivatives and uses thereof
CN118240002A (zh) 螺环类化合物、其制备方法及其在医药上的应用
US20250042862A1 (en) Aromatic heterocyclic compound and application thereof
HK40074639A (en) Synthesis and use of a class of respiratory syncytial virus inhibitors
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
CA3285927A1 (en) Kif18a inhibitor
HK40088065A (zh) 抗病毒素1，3-二氧代茚化合物
HK40088065B (zh) 抗病毒素1，3-二氧代茚化合物
TW202227444A (zh) 四環類化合物及其醫藥用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7726487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150